Clostridium difficile-associated diarrhea and colitis.

Mayo Clin Proc

Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.

Published: July 2001

Clostridium difficile is a spore-forming toxigenic bacterium that causes diarrhea and colitis, typically after the use of broad-spectrum antibiotics. The clinical presentation ranges from self-limited diarrhea to fulminant colitis and toxic megacolon. The incidence of this disease is increasing, resulting in major medical and economic consequences. Although most cases respond quickly to medical treatment, C difficile colitis may be serious, especially if diagnosis and treatment are delayed. Recurrent disease represents a particularly challenging problem. Prevention is best accomplished by limiting the use of broad-spectrum antibiotics and following good hygienic techniques and universal precautions to limit the transmission of bacteria. A high index of suspicion results in early diagnosis and treatment and potentially reduces the incidence of complications.

Download full-text PDF

Source
http://dx.doi.org/10.4065/76.7.725DOI Listing

Publication Analysis

Top Keywords

diarrhea colitis
8
broad-spectrum antibiotics
8
diagnosis treatment
8
clostridium difficile-associated
4
difficile-associated diarrhea
4
colitis
4
colitis clostridium
4
clostridium difficile
4
difficile spore-forming
4
spore-forming toxigenic
4

Similar Publications

German surveillance data from 2022 reported a prevalence of nosocomial infections among hospitalized patients of 5,2%. Clostridioides-difficile-infections (CDI) are the most frequent cause of nosocomial diarrhea. They are usually caused by antibiotic exposure and the subsequent changes in the gut microbiota.

View Article and Find Full Text PDF

Mycophenolate mofetil (MMF) is a widely utilized immunosuppressive medication to prevent organ rejection in transplant recipients and manage autoimmune diseases. While gastrointestinal side effects, such as diarrhea and abdominal discomfort, are common, fulminant colitis is a rare complication. This case report describes the occurrence of fulminant colitis in a 76-year-old renal transplant recipient.

View Article and Find Full Text PDF

Background And Aims: Protein tyrosine phosphatase non-receptor type 23 (PTPN23) regulates the internalization of growth factor receptors such as the epithelial growth factor receptor (EGFR). Given the crucial function of such receptors in intestinal epithelial cells (IECs), we assessed the involvement of PTPN23 in intestinal homeostasis and epithelial proliferation.

Methods: We generated mouse models with constitutive (PTPN23fl/flVilCre+/-) or inducible (PTPN23fl/flVilCreERT+/-) deletion of PTPN23 in IEC.

View Article and Find Full Text PDF

Early identification and multidisciplinary management of immune checkpoint inhibitors associated colitis can improve patient outcomes.

World J Gastrointest Surg

January 2025

Department of Gastrointestinal Oncology Surgery, The Affiliated Hospital of Qinghai University, The Affiliated Cancer Hospital of Qinghai University, Xining 810000, Qinghai Province, China.

Currently, the use of immune checkpoint inhibitors (ICIs) has shown notable clinical efficacy in treating various malignant tumors, significantly improving patient prognosis. However, while ICIs enhance the body's anti-tumor effects, they can also trigger immune-related adverse events (irAEs), with ICI-associated colitis being one of the more prevalent forms. This condition can disrupt treatment, necessitate drug discontinuation, and adversely affect therapeutic outcomes.

View Article and Find Full Text PDF

Purpose: Outcomes for patients with advanced sarcomas are poor and there is a high unmet need to develop novel therapies. The purpose of this phase I study was to define the safety and efficacy of botensilimab (BOT), an Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody, plus balstilimab (BAL), an anti-PD-1 antibody, in advanced sarcomas.

Methods: BOT was administered intravenously (IV) at 1 mg/kg or 2 mg/kg once every 6 weeks in combination with BAL IV at 3 mg/kg once every 2 weeks for up to 2 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!